Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.84 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.84 |
| ▸ | CTSD | P07339 | 3/20 | 0.68 |
| ▸ | CTSE | P14091 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14457253 | 0.94 | BACE1 (0.74) | BACE1BACE2CTSDCTSE | |
| SCHEMBL15678320 | 0.94 | BACE1 (0.74) | BACE1BACE2CTSDCTSE | |
| SCHEMBL719404 | 0.92 | BACE1 (1.00) | BACE1BACE2CTSDCTSE | |
| SCHEMBL719405 | 0.92 | BACE1 (1.00) | BACE1BACE2CTSDCTSE | |
| SCHEMBL2846689 | 0.92 | BACE1 (1.00) | BACE1BACE2CTSDCTSE | |
| SCHEMBL719403 | 0.92 | BACE1 (1.00) | BACE1BACE2CTSDCTSE | |
| SCHEMBL2204117 | 0.90 | BACE1 (0.79) | BACE1BACE2CTSDCTSE | |
| SCHEMBL2204110 | 0.90 | BACE1 (0.79) | BACE1BACE2CTSDCTSE | |
| SCHEMBL2204119 | 0.90 | BACE1 (0.79) | BACE1BACE2CTSDCTSE | |
| SCHEMBL8293945 | 0.89 | BACE1 (0.77) | BACE1BACE2CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278334-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | Merck, Sharp & Dohme Corp. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100152138-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP. | 2010-06-17 | — | — | US | disclosed |
| US-7662816-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | SCHERING CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152138-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | BACE1 1/4885BACE2 2/4885CTSD 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.